FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2187919243> ?p ?o ?g. }

• W2187919243 endingPage "3136" @default.
• W2187919243 startingPage "3133" @default.
• W2187919243 abstract "Background: The high prevalence of bone metastases in stage IV non-small cell lung cancer (NSCLC) patients contributes substantially to the burden of the disease by resulting in significant skeletal morbidity. Ibandronate is a new generation of bisphosphonates (BPs) with demonstrated clinical benefit in breast and prostate cancer patients with bone metastases. Patients and Methods: In 32 patients with newly diagnosed non-small cell lung cancer and bone metastases, 4 mg of ibandronate were administered, as a rapid 20-minute intravenous infusion every 3-4 weeks. Results: A total of 189 infusions were administered over a 24-month period during which a statistically significant decrease in calcium serum levels (p=0.03) was observed. The serum levels of alkaline phosphatase (ALP) were also decreased but not significantly. With regard to clinical efficacy, 24 of our patients stabilized or reduced their need for analgesic treatment. The reduced time of infusion (20 min vs. 2 h) did not correlate with any side- effects, including vital sign deterioration and renal dysfunction. Conclusion: The rapid infusion of ibandronate in lung cancer patients with bone metastases is a safe and convenient procedure that may be administered in a day clinic setting. Bisphosphonates (BPs) are potent osteoclast-mediated osteolysis inhibitors that constitute an established treatment for bone metabolism disorders, such as Paget's disease and osteoporosis. When used in the setting of malignant bone disease, it has been demonstrated that BPs, administered in a more intense dosing, delay and prevent skeletal complications, while also treating malignant hypercalcemia. The intravenous administration of BP has been the standard of care in patients with bone lesions from multiple myeloma or secondary, solid malignancy bone metastases, such as those found in breast and prostate cancers. With regard to safety, intravenous administration is generally well-tolerated in long-term use, while the development of more potent, second- and third-generation BPs has greatly improved the convenience (due to the shorter infusion time) and clinical activity of these agents (1, 2)." @default.
• W2187919243 created "2016-06-24" @default.
• W2187919243 creator A5015800207 @default.
• W2187919243 creator A5017454817 @default.
• W2187919243 creator A5027042186 @default.
• W2187919243 creator A5027876275 @default.
• W2187919243 creator A5030848587 @default.
• W2187919243 creator A5034623304 @default.
• W2187919243 creator A5038983218 @default.
• W2187919243 creator A5064568600 @default.
• W2187919243 date "2006-07-01" @default.
• W2187919243 modified "2023-09-28" @default.
• W2187919243 title "Rapid infusion of ibandronate in lung cancer patients with bone metastases." @default.
• W2187919243 cites W1521095066 @default.
• W2187919243 cites W1883130365 @default.
• W2187919243 cites W1965374994 @default.
• W2187919243 cites W1980576844 @default.
• W2187919243 cites W2044794329 @default.
• W2187919243 cites W2066942860 @default.
• W2187919243 cites W2075224794 @default.
• W2187919243 cites W2098162148 @default.
• W2187919243 cites W2130934441 @default.
• W2187919243 cites W2141884093 @default.
• W2187919243 cites W2155440394 @default.
• W2187919243 cites W2155728216 @default.
• W2187919243 cites W2314428698 @default.
• W2187919243 cites W2341765369 @default.
• W2187919243 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16886646" @default.
• W2187919243 hasPublicationYear "2006" @default.
• W2187919243 type Work @default.
• W2187919243 sameAs 2187919243 @default.
• W2187919243 citedByCount "3" @default.
• W2187919243 countsByYear W21879192432013 @default.
• W2187919243 countsByYear W21879192432022 @default.
• W2187919243 crossrefType "journal-article" @default.
• W2187919243 hasAuthorship W2187919243A5015800207 @default.
• W2187919243 hasAuthorship W2187919243A5017454817 @default.
• W2187919243 hasAuthorship W2187919243A5027042186 @default.
• W2187919243 hasAuthorship W2187919243A5027876275 @default.
• W2187919243 hasAuthorship W2187919243A5030848587 @default.
• W2187919243 hasAuthorship W2187919243A5034623304 @default.
• W2187919243 hasAuthorship W2187919243A5038983218 @default.
• W2187919243 hasAuthorship W2187919243A5064568600 @default.
• W2187919243 hasConcept C121608353 @default.
• W2187919243 hasConcept C126322002 @default.
• W2187919243 hasConcept C126894567 @default.
• W2187919243 hasConcept C141071460 @default.
• W2187919243 hasConcept C170033053 @default.
• W2187919243 hasConcept C2776139714 @default.
• W2187919243 hasConcept C2776169692 @default.
• W2187919243 hasConcept C2776256026 @default.
• W2187919243 hasConcept C2776541429 @default.
• W2187919243 hasConcept C2780192828 @default.
• W2187919243 hasConcept C2781282405 @default.
• W2187919243 hasConcept C530470458 @default.
• W2187919243 hasConcept C673006 @default.
• W2187919243 hasConcept C71924100 @default.
• W2187919243 hasConcept C90924648 @default.
• W2187919243 hasConceptScore W2187919243C121608353 @default.
• W2187919243 hasConceptScore W2187919243C126322002 @default.
• W2187919243 hasConceptScore W2187919243C126894567 @default.
• W2187919243 hasConceptScore W2187919243C141071460 @default.
• W2187919243 hasConceptScore W2187919243C170033053 @default.
• W2187919243 hasConceptScore W2187919243C2776139714 @default.
• W2187919243 hasConceptScore W2187919243C2776169692 @default.
• W2187919243 hasConceptScore W2187919243C2776256026 @default.
• W2187919243 hasConceptScore W2187919243C2776541429 @default.
• W2187919243 hasConceptScore W2187919243C2780192828 @default.
• W2187919243 hasConceptScore W2187919243C2781282405 @default.
• W2187919243 hasConceptScore W2187919243C530470458 @default.
• W2187919243 hasConceptScore W2187919243C673006 @default.
• W2187919243 hasConceptScore W2187919243C71924100 @default.
• W2187919243 hasConceptScore W2187919243C90924648 @default.
• W2187919243 hasLocation W21879192431 @default.
• W2187919243 hasLocation W21879192432 @default.
• W2187919243 hasOpenAccess W2187919243 @default.
• W2187919243 hasPrimaryLocation W21879192431 @default.
• W2187919243 hasRelatedWork W1568146676 @default.
• W2187919243 hasRelatedWork W1979626510 @default.
• W2187919243 hasRelatedWork W1995580211 @default.
• W2187919243 hasRelatedWork W1996589664 @default.
• W2187919243 hasRelatedWork W2010219393 @default.
• W2187919243 hasRelatedWork W2012023442 @default.
• W2187919243 hasRelatedWork W2029838719 @default.
• W2187919243 hasRelatedWork W2042101958 @default.
• W2187919243 hasRelatedWork W2042712761 @default.
• W2187919243 hasRelatedWork W2043380178 @default.
• W2187919243 hasRelatedWork W2105147506 @default.
• W2187919243 hasRelatedWork W2119161416 @default.
• W2187919243 hasRelatedWork W2120118174 @default.
• W2187919243 hasRelatedWork W2137083298 @default.
• W2187919243 hasRelatedWork W2242287155 @default.
• W2187919243 hasRelatedWork W2316096113 @default.
• W2187919243 hasRelatedWork W2358596651 @default.
• W2187919243 hasRelatedWork W2373982830 @default.
• W2187919243 hasRelatedWork W2375493697 @default.
• W2187919243 hasRelatedWork W2376032488 @default.
• W2187919243 hasVolume "26" @default.

• next